Yazar "Kanyilmaz, G." seçeneğine göre listele
Listeleniyor 1 - 5 / 5
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Adjuvant chemotherapy after preoperative chemoradiotherapy for rectal cancer(Oxford Univ Press, 2015) Kanyilmaz, G.; Koc, M.; Aktan, M.Adjuvant chemotherapy has been very questionable recently. In this regards, the study which was designed by A.J. Breugom and colleagues :'Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Clorectal Cancer Group (DCCG) randomized phase III trial' caught our attention. We read this trial with very interest. However from our point our view there are some limitations of this study and we want to make some suggestion and some criticism for study.Öğe The Effect of Hormonotherapy on the Development of Lung Fibrosis after Radiotherapy in Breast Cancer Patients(Elsevier Science Inc, 2020) Yavuz, B. Benli; Poyraz, N.; Kanyilmaz, G.; Aktan, M.; Tuncez, I.; Koc, M., Sr.[Abstract Not Availabe]Öğe The Effects of ORAL Glutamine Supplementation on Clinical and Survival Outcomes of Non-Small Cell Cancer Patients Treated With Chemoradiation Therapy(Elsevier Science Inc, 2015) Kanyilmaz, G.; Koc, M., Sr.; Aktan, M.; Temiz, S. A.; Adli, M.[Abstract Not Availabe]Öğe Prognostic importance of 18F-fiuorodeoxyglucose uptake by positron emission tomography for stage III non-small cell lung cancer treated with definitive chemoradiotherapy(Elsevier Espana Slu, 2020) Kanyilmaz, G.; Yavuz, B. Benli; Aktan, M.; Sahin, O.Objectives: Survival heterogeneity exists among patients with non-small cell lung cancer (NSCLC), even within the same stage. We aimed to evaluate the prognostic role of pre-treatment maximum standardized uptake value (SUVmax) in patients treated with definitive concurrent chemoradiotherapy for stage III NSCLC. Materials and methods: Between 2010 and 2017, 103 patients with stage III NSCLC who underwent F-18-FDG PET/CT at the time of diagnosis were included in the study. Results: Higher tumor stages were correlated with higher pre-treatment SUVmax of lymph nodes (LNs) (p = 0.005) but were not correlated with higher SUVmax of primary tumor (p = 0.2). The median SUV max of LNs was 2.84, 8.06, and 11.11 in stage IIIa, IIIb and IIIc, respectively. Higher nodal stage was also correlated with higher SUVmax of LNs (p - 0.01). According to ROC analysis, there was no significant cut-off value of SUVmax observed for primary tumor, therefore continuous variables were used for survival analyses. The best SUVmax cut-off was 3.5 for the LNs, therefore the SUVmax of LNs was evaluated as both a dichotomous and a continuous variable. Pre-treatment SUVmax of primary tumor did not predict survival outcomes but both the continuous and dichotomous variables of SUV(max )of LNs predicted recurrence free survival and overall survival. Nodal stage (N0-2 vs. N3) and AJCC stage (IIIa vs IIIb vs. IIIc) were the other prognostic factors. Conclusions: Pre-treatment SUVmax of LNs had prognostic value in patients treated with definitive concurrent chemoradiotherapy for stage III NSCLC. In future trials, pre-treatment SUVmax of the LNs would serve as a guide for patients who might benefit from more aggressive treatments. (C) 2019 Published by Elsevier Espana, S.L.U. on behalf of Sociedad Espanola de Medicina Nuclear e lmagen Molecular.Öğe Prognostic Importance of Ki-67 Labeling Index in WHO Grade II Glial Tumors(Elsevier Science Inc, 2017) Kanyilmaz, G.; Onder, H.; Aktan, M.; Sr, M. Koc; Bora, H.; Eray, K.; Yirmibesoglu, E.[Abstract Not Availabe]
